The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer

Gioulbasanis, Ioannis; Pallis, Athanasios; Vlachostergios, Panagiotis J.; Xyrafas, A.; Giannousi, Zoe; Perdikouri, Isidora-Eleni; Makridou, Michalitsa; Kakalou, Dionysia; Georgoulias, V.

doi:10.1016/j.lungcan.2012.04.008

Cited by 59 publications

(66 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is increasingly recognized that the host systemic inflammatory response plays a critical role in the development and progression of many cancers [26, 27]. An elevated NLR conferred adverse survival in gastrointestinal cancer, pancreatic cancer, breast cancer, bladder cancer and other cancers [7, 9, 28, 29].…”

Section: Discussionmentioning

confidence: 99%

The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer

Liu

Jin

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The objectives of this study were to evaluate the impact of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) on overall survival (OS) and to explore the value of changes in the NLR and PLR with treatment as a response indicator. Methods: A total of 934 patients were eligible for retrospective analysis between 2008 and 2014. The pretreatment and post-treatment PLR and NLR in all patients were calculated based on complete blood counts. Univariate and multivariate Cox regression analyses were performed to determine the associations of the PLR and NLR with OS. Results: The pretreatment NLR and PLR were correlated with different disease status and response to chemotherapy. Patients with lower NLR and PLR had a significantly better complete response (CR) rate to chemotherapy versus those with a higher NLR and PLR (p< 0.001). The NLR and PLR were sustained in patients who obtained a CR compared with moderate or poor response patients. The lower NLR of pretreatment was independently associated with a favourable prognosis in whole patients with lung cancer (HR: 0.69, 95% CI, 0.55-0.85, p< 0.001). In the patients under control after chemotherapy, the NLR of post-chemotherapy had a greater impact on survival, and the low NLR level maintained during chemotherapy was identified a predictor for favourable survival. PLR was not an independent prognostic indicator in the whole cohort or any subgroups. Conclusion: Our results suggested that NLR was well-connected with outcomes and response to chemotherapy in patients with lung cancer. As a response indicator, NLR may predict benefit from chemotherapy and improve patient selection.

show abstract

Section: Discussionmentioning

confidence: 99%

The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer

Liu

Jin

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Previous studies also found significant associations between GPS and the chemotherapy dose adjustment, the requirement for granulocyte colony-stimulating factor support, termination of treatment due to side-effects, and fatal toxicity (21). In the present study, GPS was associated with more frequent utilization of palliative care resources, the number of blood transfusions and intravenous treatment with antibiotics.…”

Section: Discussionmentioning

confidence: 87%

The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy

Nieder

Mannsåker

Dalhaug

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

The purpose of the present retrospective study was to investigate whether a score reflecting systemic inflammatory processes [the Glasgow Prognostic Score (GPS)] provides relevant information for radiation oncologists. GPS is a three-tiered score [0: normal C-reactive protein (CRP) and albumin; 1: one abnormal result; 2: increased CRP and low albumin]. Correlations between disease type and extent, resource utilization, survival and GPS were analyzed in 703 patients. In the subgroup with GPS 2, significantly higher rates of lung, adrenal gland and liver metastases were observed. An increasing GPS score was associated with a higher likelihood of anemia, leukocytosis and thrombocytosis. Comparable findings were made regarding utilization of palliative care resources, need for blood transfusion and intravenous administration of antibiotics. Compared with GPS 0 or 1, more patients with GPS 2 did not complete their prescribed course of radiotherapy. One-third of patients with GPS 2 received treatment during the final month of life. Multivariate analysis demonstrated that GPS was a significant prognostic factor for overall survival (median, 479, 136, and 61 days, for GPS 0, 1 and 2, respectively). In patients with GPS 2 and additional leukocytosis, the median survival was 38 days. In conclusion, GPS provides important prognostic information. This biomarker-based score may be considered for deciding fractionation, and should be validated further.

show abstract

“…The GPS has been proposed as a reliable prognostic factor in patients with advanced cancer including colorectal cancer [9], esophageal cancer [10], lung cancer [11], pancreatic cancer [12], gastric cancer [13], and breast cancer [14]. …”

Section: Discussionmentioning

confidence: 99%

“…Gioulbasanis et al [11] found that the GPS was associated with increased mucositis, neurotoxicity, neutropenia, dose reductions, or/and the need for granulocyte colony-stimulating factor support, toxicity-related termination of treatment, chemotherapy-related toxic deaths, overall survival, and PFS, as well as with the response to treatment, in 96 lung cancer patients treated with first-line platinum-based chemotherapy. In 100 stage IV non-small cell lung cancer patients treated with a combination of cisplatin and paclitaxel, low albumin levels were associated with anemia, fatigue, and appetite loss compared to normal albumin [28].…”

Section: Discussionmentioning

confidence: 99%

The Glasgow Prognostic Score Predicts Response to Chemotherapy in Patients with Metastatic Breast Cancer

Wang

Duan

et al. 2016

Chemotherapy

View full text Add to dashboard Cite

Purpose: Breast cancer is one of the most common causes of cancer death in women worldwide. The Glasgow Prognostic Score (GPS), a cumulative prognostic score based on C-reactive protein and albumin, indicates the presence of a systemic inflammatory response. The GPS has been adopted as a powerful prognostic tool for patients with various types of malignant tumors, including breast cancer. The aim of this study was to assess the value of the GPS in predicting the response and toxicity in breast cancer patients treated with chemotherapy. Patients and Methods: Patients with metastatic breast cancers in a progressive stage for consideration of chemotherapy were eligible. The clinical characteristics and demographics were recorded. The GPS was calculated before the onset of chemotherapy. Data on the response to chemotherapy and progression-free survival (PFS) were also collected. Objective tumor responses were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST). Toxicities were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTC) version 3.0 throughout therapy. Results: In total, 106 breast cancer patients were recruited. The GPS was associated with the response rate (p = 0.05), the clinical benefit rate (p = 0.03), and PFS (p = 0.005). The GPS was the only independent predictor of PFS (p = 0.005). The GPS was significantly associated with neutropenia, thrombocytopenia, anorexia, nausea and vomiting, fatigue, and mucositis (p = 0.05-0.001). Conclusions: Our data demonstrate that GPS assessment is associated with poor clinical outcomes and severe chemotherapy-related toxicities in patients with metastatic breast cancer who have undergone chemotherapy, without any specific indication regarding the type of chemotherapy applied.

show abstract

The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer

Cited by 59 publications

References 35 publications

The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer

The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer

The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy

The Glasgow Prognostic Score Predicts Response to Chemotherapy in Patients with Metastatic Breast Cancer

Contact Info

Product

Resources

About